Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Inclusion Criteria: * Relapsed and refractory Multiple Myeloma treated with at least 3 prior regimens of system therapy including Proteosome Inhibitor (PI), immunomodulatory drugs (IMiD), and anti-CD38 antibody (CD38mab); or has "triple-refractory" disease * Documented measurable disease * Adequate organ function * Life expectancy \> 12 weeks, Eastern Cooperative Group Performance Status 0-1 Exclusion Criteria: * Plasma Cell Leukemia or History of Plasma Cell Leukemia * Patients with a history of severe hypersensitivity to DMSO should be excluded * Contraindication to fludarabine or cyclophosphamide * Severe uncontrolled intercurrent illness (e.g., infection) or laboratory abnormalities * Active central nervous system disease involvement by malignancy or active CNS pathology